When it comes to CLL/SLL treatment, what’s the difference between BTK inhibitors and BCL-2 inhibitors? Understanding how these treatment approaches work and how they fit into the treatment…
BTK degrader BGB-16673 reduced tumor burden in 85% of patients from a high-risk, hard-to-treat group with relapsed / refractory CLL. Dr. Stephan Stilgenbauer from Ulm University and colleagues…
Heat Biologics has devised a method intended to capture poly-antigens and present them to immunomodulatory mechanisms and revitalize the immune system, allowing it to target and annihilate cancer.
Dr. Adler provides a detailed review of the diagnostic criteria associated with adult attention-deficit / hyperactivity disorder (ADHD) due to the complex constellation of symptoms that mimic or…
Each month we present you with the latest featured study from the research teams at JAMA, Journal of the American Medical Association. Check out the video for intriguing…
The United States National Institutes of Health (US NIH) has collaborated with an established pharmaceutical company, Sanofi, in an attempt to foment a revolutionary medical breakthrough in HIV…
Each month we present you with the latest featured study from the research teams at JAMA, Journal of the American Medical Association. Check out the video for intriguing…
